JPMorgan highlights stock on Analyst Focus List after 3Q results
JPMorgan analyst Brian Cheng maintained Tango Therapeutics (TNGX) on its Analyst Focus List with an Overweight rating after 3Q results met expectations. Key catalysts include January updates on '456 and vopi therapies. The price target was raised to $47 from $46. The company is progressing studies in pancreatic and other cancers.
